Makhzoumi Mohamad — SEC Form 4 filings

SEC reporting owner CIK 1630226. 12 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.

Transaction summary — filings shown

Covers all 12 filings on record, filed 2024-04-10 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
SpyGlass Pharma, Inc. (SGP)10% owner11 leg · 937,500 sh · $15,000,00012
MBX Biosciences, Inc. (MBX)10% owner11 leg · 500,000 sh · $8,000,0004
Korro Bio, Inc. (KRRO)10% owner22 legs · 224,957 sh · $3,300,8731
Marker Therapeutics, Inc. (MRKR)10% owner11 leg · 554,250 sh · $1,773,600
NeueHealth, Inc. (NEUE)Director, 10% owner554
SYNLOGIC, INC. (SYBX)Director, 10% owner12
Senti Biosciences, Inc. (SNTI)10% owner12

Form 4 filings — Makhzoumi Mohamad

FiledFormIssuerReported transactionsSource
2026-08-144SYNLOGIC, INC. (SYBX)
jointly with New Enterprise Associates 14, L.P., NEA Partners 14, L.P., NEA 14 GP, LTD, Florence Anthony A. Jr., SANDELL SCOTT D
Code (H): 2,640,845 (derivative) · Purchase (P): 2,640,845 (derivative)EDGAR
2026-03-124Korro Bio, Inc. (KRRO)Purchase (P): 207,100 @ $11.11 · Purchase (P): 242,945 (derivative) @ $11.11EDGAR
2026-02-114SpyGlass Pharma, Inc. (SGP)Conversion (C): 1,619,240 · Conversion (C): 1,370,168 · Conversion (C): 1,370,168 · Conversion (C): 737,962 · Purchase (P): 937,500 @ $16 · Conversion (C): 954,990 · +7 moreEDGAR
2025-10-064NeueHealth, Inc. (NEUE)Option exercise (M): 189,195 @ $0.01 · Tax withholding (F): 280 @ $6.75 · Option exercise (M): 434,297 @ $0.01 · Tax withholding (F): 643 @ $6.75 · Disposition to issuer (D): 1,960,591 · Disposition to issuer (D): 43,678 · +35 moreEDGAR
2025-05-154NeueHealth, Inc. (NEUE)Option exercise (M): 10,500 @ $0 · Option exercise (M): 10,500 (derivative) @ $0EDGAR
2025-03-124Senti Biosciences, Inc. (SNTI)
jointly with New Enterprise Associates 15, L.P., NEA Partners 15, L.P., NEA 15 GP, LLC, BASKETT FOREST, Florence Anthony A. Jr., SANDELL SCOTT D
Conversion (C): 3,333,000 · Conversion (C): 3,333 (derivative)EDGAR
2024-12-234Marker Therapeutics, Inc. (MRKR)
jointly with New Enterprise Associates 16, L.P., NEA Partners 16, L.P., NEA 16 GP, LLC, BASKETT FOREST, Chang Carmen, Behbahani Ali, Florence Anthony A. Jr., SANDELL SCOTT D, Walker Paul Edward
Purchase (P): 554,250 @ $3.20EDGAR
2024-10-034NeueHealth, Inc. (NEUE)Grant/award (A): 61,865 (derivative) · Grant/award (A): 61,865 (derivative) · Grant/award (A): 61,865 (derivative) · Grant/award (A): 185,595 (derivative)EDGAR
2024-09-174MBX Biosciences, Inc. (MBX)Conversion (C): 1,023,103 · Conversion (C): 2,091,383 · Purchase (P): 500,000 @ $16 · Conversion (C): 12,299,854 (derivative) · Conversion (C): 25,142,840 (derivative)EDGAR
2024-05-144NeueHealth, Inc. (NEUE)Option exercise (M): 4,755 @ $0 · Option exercise (M): 4,755 (derivative) @ $0 · Grant/award (A): 10,500 (derivative) @ $0EDGAR
2024-04-244Korro Bio, Inc. (KRRO)Purchase (P): 17,857 @ $56EDGAR
2024-04-104NeueHealth, Inc. (NEUE)Grant/award (A): 123,729 (derivative) · Grant/award (A): 123,729 (derivative) · Grant/award (A): 123,729 (derivative) · Grant/award (A): 371,187 (derivative)EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1630226 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →